Out Comes After CAR T Cell Therapy in The Long Run

Objective: During the past several years, there has been a lot of discussion regarding
the utilization of chimeric antigen receptor T-cells as an immunotherapy treatment for
malignancies. Method: The scope of this study encompasses not only the negative
consequences that CAR-T cells have, but also the mechanisms that are responsible for
those effects, as well as potential treatments. Results: Through the utilization of this
therapy strategy, both hematological malignancies and solid tumors have been
successfully treated. However, it has been associated with a number of adverse reactions,
such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity
syndrome (ICANS), off-target effects, anaphylaxis, infections associated with CAR-T
cell infusion (CTI), tumor lysis syndrome (TLS), B-cell dysplasia, hemophagocytic
lympho histiocytosis (HLH)/macrophage activation syndrome (MAS), and coagulation
disorders. Novelty: The therapeutic application of CAR-T cell therapy can be informed
by this evaluation, which will furnish critical reference data.